These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
99 related items for PubMed ID: 1740697
1. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N. J Nucl Med; 1992 Mar; 33(3):325-9. PubMed ID: 1740697 [Abstract] [Full Text] [Related]
6. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337 [Abstract] [Full Text] [Related]
7. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T, Ryu M. J Nucl Med; 1992 Mar; 33(3):333-9. PubMed ID: 1311035 [Abstract] [Full Text] [Related]
8. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, Bergman J, Haaparanta M, Ruotsalainen U, Solin O, Joensuu H. Blood; 1995 Nov 01; 86(9):3522-7. PubMed ID: 7579459 [Abstract] [Full Text] [Related]
10. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, Moser E, Glatting G, Kotzerke J, Guhlmann CA, Schirrmeister H, Reske SN. Cancer; 2001 Mar 01; 91(5):889-99. PubMed ID: 11251940 [Abstract] [Full Text] [Related]
11. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. Lindholm P, Leskinen-Kallio S, Minn H, Bergman J, Haaparanta M, Lehikoinen P, Någren K, Ruotsalainen U, Teräs M, Joensuu H. J Nucl Med; 1993 Oct 01; 34(10):1711-6. PubMed ID: 8410288 [Abstract] [Full Text] [Related]
13. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, Jingu K, Masuda K. J Nucl Med; 1991 Sep 01; 32(9):1655-60. PubMed ID: 1880564 [Abstract] [Full Text] [Related]
14. A study of vestibular schwannomas using positron emission tomography and monoclonal antibody Ki-67. Chen JM, Houle S, Ang LC, Commins D, Allan K, Nedzelski J, Rowed D. Am J Otol; 1998 Nov 01; 19(6):840-5. PubMed ID: 9831165 [Abstract] [Full Text] [Related]
15. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT. AJR Am J Roentgenol; 1994 Dec 01; 163(6):1459-65. PubMed ID: 7992747 [Abstract] [Full Text] [Related]
17. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate. Kuwabara H, Gjedde A. J Nucl Med; 1991 Apr 01; 32(4):692-8. PubMed ID: 2013809 [Abstract] [Full Text] [Related]
18. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. J Thorac Cardiovasc Surg; 1995 Jul 01; 110(1):130-9; discussion 139-40. PubMed ID: 7609536 [Abstract] [Full Text] [Related]
19. [18F-FDG uptake of lymphoma lesions of various histological subtypes]. Ma LF, Fan W. Ai Zheng; 2009 Apr 01; 28(4):425-30. PubMed ID: 19622306 [Abstract] [Full Text] [Related]